Study # CABL001AUS08

A Phase II Multicenter, Open-Label, Single-Arm Dose Escalation study of Asciminib Monotherapy in 2nd and 1st Line Chronic Phase-Chronic Myelogenous Leukemia

Study Status:

Enrolling

Treatment Agent:

Asciminib

Description

Short Title: ASC2ESCALATE

This will be a multicenter Phase II open-label study of asciminib in CML-CP patients who have been previously treated with one prior ATP- binding site TKI with discontinuation due to treatment failure, warning or intolerance. (2L patient cohort). In addition, newly diagnosed CML-CP patients who may have received up to 4 weeks of prior TKI are included in a separate 1L patient cohort.

*PLEASE NOTE OUR SITE IS ACTIVATING TO ENROLL ON 2L cohort  ( 1L cohort is closed)*

Resources and Links

National Clinical Trial Identified Number: NCT05384587

Information and next steps

Disease:

  • Chronic Myelogenous Leukemia - Chronic Phase

Study Phase:

II

Physician Name:

Department:

Ask a Question